Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)β’ Click on a phase to view related trials
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Zelenectide pevedotin (BT8009)
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 73
- Registration Number
- NCT06933329
- Locations
- πΊπΈ
Texas Oncology - DFW, Dallas, Texas, United States
πΊπΈVirginia Cancer Specialists, Arlington, Virginia, United States
πΊπΈTexas Oncology - Central South, Austin, Texas, United States
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Zelenectide pevedotin (BT8009)
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 66
- Registration Number
- NCT06840483
- Locations
- πΊπΈ
Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 956
- Registration Number
- NCT06225596
- Locations
- πΊπΈ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈVirginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton, California, United States
πΊπΈUniversity of California - Irvine Medical Center, Orange, California, United States
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 200
- Registration Number
- NCT05163041
- Locations
- πΊπΈ
State University of Iowa, Iowa City, Iowa, United States
πΊπΈColumbia University Irving Medical Center, New York, New York, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
- Conditions
- Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative NeoplasmsHormone Receptor Positive, HER2-low NeoplasmsBreast NeoplasmsNon-Small-Cell Lung NeoplasmsOvarian NeoplasmAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- BicycleTx Limited
- Target Recruit Count
- 329
- Registration Number
- NCT04561362
- Locations
- πΊπΈ
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
πΊπΈOcala Oncology Center, Ocala, Florida, United States
πΊπΈAdvent Health, Orlando, Florida, United States
- Prev
- 1
- 2
- Next